Published in Clin Transl Immunology on June 20, 2014
iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma/VEGAS | NCT01953900
Versatile strategy for controlling the specificity and activity of engineered T cells. Proc Natl Acad Sci U S A (2016) 1.08
Improving the safety of cell therapy products by suicide gene transfer. Front Pharmacol (2014) 0.94
HIV-specific Immunity Derived From Chimeric Antigen Receptor-engineered Stem Cells. Mol Ther (2015) 0.88
Synthetic biology in cell-based cancer immunotherapy. Trends Biotechnol (2015) 0.84
Progress and problems with the use of suicide genes for targeted cancer therapy. Adv Drug Deliv Rev (2015) 0.81
Tolerogenic Dendritic Cells on Transplantation: Immunotherapy Based on Second Signal Blockage. J Immunol Res (2015) 0.79
Adoptive T-cell immunotherapy for ganciclovir-resistant CMV disease after lung transplantation. Clin Transl Immunology (2015) 0.78
Macrophage-based cell therapies: The long and winding road. J Control Release (2016) 0.78
Delivering safer immunotherapies for cancer. Adv Drug Deliv Rev (2017) 0.76
Caspase-9: structure, mechanisms and clinical application. Oncotarget (2017) 0.75
Antigen-specific T cells fully conserve antitumour function following cryopreservation. Immunol Cell Biol (2016) 0.75
Technological advances in precision medicine and drug development. Expert Rev Precis Med Drug Dev (2016) 0.75
Human Tregs Made Antigen Specific by Gene Modification: The Power to Treat Autoimmunity and Antidrug Antibodies with Precision. Front Immunol (2017) 0.75
FCγ Chimeric Receptor-Engineered T Cells: Methodology, Advantages, Limitations, and Clinical Relevance. Front Immunol (2017) 0.75
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (2002) 19.77
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med (2011) 18.99
Cancer regression in patients after transfer of genetically engineered lymphocytes. Science (2006) 16.96
Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med (2013) 10.63
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest (2008) 9.42
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood (2009) 9.24
Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther (2010) 9.13
CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med (2013) 7.99
Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst (1994) 7.20
Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest (2008) 7.05
Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science (1992) 7.04
Controlling signal transduction with synthetic ligands. Science (1993) 6.70
Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med (2011) 6.14
Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med (2014) 5.60
Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol (2006) 5.02
Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother (2013) 4.80
Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med (2010) 4.76
HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science (1997) 4.58
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol (1997) 4.51
Analysis of the aphthovirus 2A/2B polyprotein 'cleavage' mechanism indicates not a proteolytic reaction, but a novel translational effect: a putative ribosomal 'skip'. J Gen Virol (2001) 4.25
Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet (1995) 4.07
Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med (1996) 4.07
Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. Lancet Oncol (2009) 3.89
Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity. Proc Natl Acad Sci U S A (1998) 3.88
Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood (2010) 3.57
Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood (1990) 3.50
Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J Immunol (1999) 3.33
Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo. J Exp Med (2000) 3.32
T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther (2010) 3.29
An inducible caspase 9 safety switch for T-cell therapy. Blood (2005) 2.93
Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nat Med (2010) 2.92
Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood (2013) 2.91
Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biol Blood Marrow Transplant (2007) 2.33
Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity. Sci Transl Med (2011) 2.14
Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci Transl Med (2013) 2.07
Gene therapy for Wiskott-Aldrich syndrome--long-term efficacy and genotoxicity. Sci Transl Med (2014) 2.00
Generation and large-scale expansion of human inducible regulatory T cells that suppress graft-versus-host disease. Am J Transplant (2011) 1.96
Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol (2013) 1.91
Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol Ther (2013) 1.89
Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc Natl Acad Sci U S A (1999) 1.82
Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev (2014) 1.81
Administration of herpes simplex-thymidine kinase-expressing donor T cells with a T-cell-depleted allogeneic marrow graft. Blood (2001) 1.71
Synthetic activation of caspases: artificial death switches. Proc Natl Acad Sci U S A (1998) 1.70
Functional analysis of Fas signaling in vivo using synthetic inducers of dimerization. Curr Biol (1996) 1.60
Mixed T cell receptor dimers harbor potentially harmful neoreactivity. Proc Natl Acad Sci U S A (2010) 1.56
Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy. Nat Biotechnol (2013) 1.39
Of mice, not men: no evidence for graft-versus-host disease in humans receiving T-cell receptor-transduced autologous T cells. Mol Ther (2010) 1.23
Impact of T-cell depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukaemias. Lancet (1987) 1.22
Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse. Bone Marrow Transplant (1986) 1.17
Controlling programmed cell death with a cyclophilin-cyclosporin-based chemical inducer of dimerization. Chem Biol (1996) 1.16
Considerations for the clinical application of chimeric antigen receptor T cells: observations from a recombinant DNA Advisory Committee Symposium held June 15, 2010. Cancer Res (2011) 1.15
Molecular mechanism for ganciclovir resistance in human T lymphocytes transduced with retroviral vectors carrying the herpes simplex virus thymidine kinase gene. Blood (2001) 1.08
Treatment of donor bone marrow with monoclonal anti-T-cell antibody and complement for the prevention of graft-versus-host disease. A prospective, randomized, double-blind trial. Ann Intern Med (1986) 1.03
Induced regulatory T cells promote tolerance when stabilized by rapamycin and IL-2 in vivo. J Immunol (2013) 0.98
The immunogenicity of virus-derived 2A sequences in immunocompetent individuals. Gene Ther (2013) 0.96
Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience. Cytotherapy (2010) 0.94
The continuing contribution of gene marking to cell and gene therapy. Mol Ther (2007) 0.81